Fusion Antibodies plc (AIM: FAB)
London
· Delayed Price · Currency is GBP · Price in GBX 9.40
+0.25 (2.73%)
Jan 22, 2025, 12:14 PM GMT+1
Fusion Antibodies Revenue
Fusion Antibodies had revenue of 1.21M GBP in the half year ending September 30, 2024, a decrease of -35.21%. This brings the company's revenue in the last twelve months to 1.80M, up 14.12% year-over-year. In the fiscal year ending March 31, 2024, Fusion Antibodies had annual revenue of 1.14M, down -60.84%.
Revenue (ttm)
1.80M
Revenue Growth
+14.12%
P/S Ratio
4.06
Revenue / Employee
66.74K
Employees
27
Market Cap
8.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1.14M | -1.77M | -60.84% |
| Mar 31, 2023 | 2.90M | -1.90M | -39.55% |
| Mar 31, 2022 | 4.80M | 634.00K | 15.22% |
| Mar 31, 2021 | 4.17M | 270.00K | 6.93% |
| Mar 31, 2020 | 3.90M | 1.71M | 78.51% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |